We serve Chemical Name:ethyl red CAS:76058-33-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:ethyl red
CAS.NO:76058-33-8
Synonyms:2-(4-Diaethylamino-phenylazo)-benzoesaeure;2-(4-diethylamino-phenylazo)-benzoic acid;Benzoesaeure-(2 azo 4)-(N.N-diaethyl-anilin);MFCD00002427;Ethyl Red Indicator;[not Cyanin dyes];Ethyl Red,pure;o-Aethylrot;4′-Diaethylamino-azobenzol-carbonsaeure-(2);Ethyl Red [not Cyanin dyes];o-(p-Diethylaminophenylazo)benzoic acid
Molecular Formula:C17H19N3O2
Molecular Weight:297.35200
HS Code:
Physical and Chemical Properties:
Melting point:135 °C
Boiling point:496.9ºC at 760 mmHg
Density:1.13 g/cm3
Index of Refraction:
PSA:65.26000
Exact Mass:297.14800
LogP:4.64640
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-(4-Diaethylamino-phenylazo)-benzoesaeure chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,o-(p-Diethylaminophenylazo)benzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,[not Cyanin dyes] Use and application,MFCD00002427 technical grade,usp/ep/jp grade.
Related News: Novadiscovery (NOVA), a leading health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development, today announces the appointment of Grégoire Boutonnet as Chief Operating Officer, effective immediately. aziridin-1-yl-dimethoxy-sulfanylidene-λ<sup>5</sup>-phosphane manufacturers Despite the $13 million first-quarter hit from the rate cut, iRhythm grew revenue year over year by 17% to $74.3 million in the quarter. iRhythm’s net losses for the quarter totaled $27.8 million, compared to a net loss of $9.1 million in the first quarter of 2020. 5-(4-chloro-phenyl)-3-(4-chloro-styryl)-[4-(2-methoxy-ethanesulfonyl)-phenyl]-4,5-dihydro-1H-pyrazole suppliers Plexxikon filed a lawsuit against the pharma giant in 2017, alledging that Tafinlar, a rival to its melanoma drug Zelboraf that was brought to market in collaboration with Roche, has stepped on its intellectual property. The jury ruled in its favor, adding that the infringement is in fact willful. 5beta,6beta-Epoxycholestanol vendor & factory.
